Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TNF | P01375 | 13/20 | 0.37 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.34 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.34 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6474475 | 0.94 | ALDH1A1 (0.39) | TNFCYP2C9CYP2C19TRIM24TRIM33 | |
| SCHEMBL6474544 | 0.87 | CYP2C19 (0.47) | KDM4EHSD17B10CYP2C9CYP2C19GAA | |
| SCHEMBL6474507 | 0.86 | KDM4E (0.41) | KDM4EHSD17B10TNFTBXAS1GAA | |
| SCHEMBL7303747 | 0.84 | TNF (0.38) | KDM4EHSD17B10TNFTBXAS1CYP2C9 | |
| SCHEMBL6474348 | 0.79 | ALDH1A1 (0.44) | KDM4EHSD17B10TNFCYP2C19GPR139 | |
| SCHEMBL7310513 | 0.78 | KDM4E (0.40) | KDM4EHSD17B10TNFTBXAS1GAA | |
| SCHEMBL6474360 | 0.72 | CYP2C19 (0.50) | KDM4EHSD17B10CYP2C9CYP2C19GAA | |
| SCHEMBL6476022 | 0.70 | ITGB3 (0.46) | — | |
| SCHEMBL12272048 | 0.68 | TBXAS1 (0.40) | KDM4ETNFTBXAS1 | |
| SCHEMBL30209304 | 0.67 | CYP1A2 (0.46) | KDM4EHSD17B10CYP2C9CYP2C19GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867208-B2 | Vitronectin receptor antagonists, their preparation and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 2005-03-15 | — | — | US | disclosed |
| US-20030027807-A1 | Vitronectin receptor antagonists, their preparation and their use | GENENTECH, INC. AND HOECHST AKTIENGESELLSCHAFT | 2003-02-06 | — | — | US | disclosed |
| US-6387895-B1 | BONE DISORDERS; CARDIOVASCULAR DISORDERS | HOECHST AKTIENGESELLSCHAFT (DE) | 2002-05-14 | — | — | US | disclosed |
| US-6207663-B1 | AS INHIBITORS OF BONE RESORPTION, TUMOR GROWTH, TUMOR METASTASIS, OR INFLAMMATION, OR FOR THE TREATMENT OR PROPHYLAXIS OF CARDIOVASCULAR DISORDERS, NEPHROPATHIES OR RETINOPATHIES | HOECHST ATKIENGESELLSCHAFT (DE) | 2001-03-27 | — | — | US | disclosed |
| US-6011045-A | Vitronectin receptor antagonists, their preparation and their use | HOECHST AKTIENGESELLSCHAFT | 2000-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027807-A1 | Vitronectin receptor antagonists, their preparation and their use | ADGRF1, ADGRE5, BSG | KDM4E 2736/4885HSD17B10 4194/4885TNF 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.